Fireman B.V.
General Information | |
Business: | We are a clinical-stage biopharmaceutical company focused on applying our proprietary anti-C5a technology to discover and develop first-in-class potent and specific inhibitors of the complement activation factor known as C5a. C5a is a powerful inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Our lead product candidate, IFX-1, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings. |
Industry: | PHARMACEUTICAL PREPARATIONS |
Employees: | 17 |
Founded: | 2017 |
Contact Information | |
Address | Winzerlaer Str. 2, 07745 Jena, Germany |
Phone Number | (+49) 3641 508180. |
Web Address | http://www.inflarx.com |
View Prospectus: | Fireman B.V. |
Financial Information | |
Market Cap | $351.2mil |
Revenues | $0.2 mil (last 12 months) |
Net Income | $-15.0 mil (last 12 months) |
IPO Profile | |
Symbol | IFRX |
Exchange | NASDAQ |
Shares (millions): | 6.7 |
Price range | $15.00 - $15.00 |
Est. $ Volume | $100.0 mil |
Manager / Joint Managers | J.P. Morgan/ Leerink Partners/ BMO Capital Markets |
CO-Managers | - |
Expected To Trade: | 11/8/2017 |
Status: | Priced |
Quiet Period Expiration Date: | Available only to Subscribers |
Lock-Up Period Expiration Date: | Available only to Subscribers |
SCOOP Rating | Available only to Subscribers |
Rating Change | Available only to Subscribers |